Investigating a new treatment for neurological and psychiatric disorders through mGlu7 receptor modulation
Official title: Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disorders
Funded at Vanderbilt University · NIH-10884237 · Data updated 2026-11-12
This study is looking at a special brain receptor that could help improve thinking and behavior in people with conditions like autism and Rett syndrome by testing a new compound that might reduce anxiety, boost cognitive skills, and lessen seizures.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project start | September 21, 2020 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $700,523 |
| NIH project number | 5R01MH124671-05 |
| Project ID | NIH-10884237 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with neurodevelopmental disorders such as autism spectrum disorder or Rett syndrome.
✕Less likely to help
Patients with conditions unrelated to the mGlu7 receptor or those who do not have neurodevelopmental disorders may not benefit from this research.
What this research studies
This research focuses on the metabotropic glutamate receptor 7 (mGlu7), which plays a crucial role in neurotransmitter release and synaptic plasticity in the brain. The study aims to develop small molecule positive allosteric modulators (PAMs) that enhance mGlu7 activity, potentially correcting cognitive and behavioral issues associated with neurodevelopmental disorders. By using a selective compound, VU6027459, the research will explore its effects on symptoms such as anxiety, cognitive deficits, and seizures in preclinical models. Patients may benefit from advancements in treatment options for conditions like autism and Rett syndrome.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options for patients with neurological and psychiatric disorders, improving their quality of life.
How similar studies have gone: Previous research has shown promise in targeting mGlu7 for treating related conditions, indicating potential for success with this approach.
Where this research is happening
-
Vanderbilt University
Nashville, United States Active
Researchers
- Principal investigator: Niswender, Colleen M — Vanderbilt University
- Study coordinator: Niswender, Colleen M
Related research
Other NIH-funded projects on the same topics.
-
Whole-chromosome fine-mapping across diverse ancestries to understand psychiatric disorders
A study to pinpoint the exact genetic changes that contribute to bipolar disorder and related conditions by using diverse populations to improve accuracy.
-
Neuronal signals guiding deep brain stimulation for neuropsychiatric disorders
A doctor-scientist at Stanford plans to study how deep brain stimulation changes brain cells and circuits in people with OCD, depression, and movement disorders to improve how DBS therapies work.
-
How a spouse's mental health and substance use may affect a partner's drinking problems
A study looks at how a spouse’s psychiatric disorders and drinking habits influence when a person starts, stops, or relapses into alcohol use problems within marriage.
-
Mapping brain microstructure in psychiatric disorders with normal ranges
A study will build a brain-mapping reference to understand how an individual’s brain differs within the normal range, with a focus on youths and how age and sex affect brain microstructure.
-
Foundation Models for Brain Imaging in Psychiatry
A large AI model will be trained on many brain scans and related data to help researchers understand ADHD, autism, and bipolar disorder.
-
How early pollution and stress change brain circuits for motivation and memory
This work looks at how early-life exposure to pollution and stress can alter brain circuits that control motivation and working memory for people with ADHD, depression, or similar conditions.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.